Dosage and administration
Ceraxon should be administered during or between meals. Before administering, you should dissolve the content of one sachet in a ½ cup of water. The dosage in the acute stage of ischemic stroke and traumatic brain injury is 1000mg (10ml or one sachet) every 12 hours. The length of the treatment course should be not less than six weeks.
The dose is 500-2000mg/day (5-10ml 1-2 times a day, or one sachet 1-2 times a day) for rehabilitation after stroke/TBI and the treatment of cognitive disorders caused by degenerative and vascular diseases. The length of the treatment depends on the patient’s condition. The dose for elderly patients is the same.
- Fructose intolerance.
The drug is generally well-tolerated, although some patients still may experience the following side effects:
- Allergic reactions;
- Changes in appetite;
- Parasympathetic stimulation;
- Changes in arterial pressure.
Citicoline may potentiate the effect of L-Dopa. Ceraxon should not be administered in conjunction with meclofenoxate (centrophenoxine).
Ceraxon ® is a pharmaceutical preparation of CDP-choline (Citicoline), a choline-containing phospholipid. It is one of the most efficient supplemental forms of choline along with Alpha-GPC (Cereton).
Choline is a nutrient crucial for cognitive performance, which is normally obtained from the diet. It was first discovered in 1862, but its role in neurology remained unknown for some time. Since 1998, choline was recognized as an essential nutrient by the Institute of Medicine, as human body cannot synthesize it on its own.
Because people tend to avoid cholesterol-rich food which is also usually rich in choline, most of the population is believed to be choline-deficient. Deficiency of choline may lead to fatty liver disease, atherosclerosis, and various neurological disorders. The use of some nootropic drugs such as Piracetam and Noopept might also require an additional choline supplementation.
CDP-choline is used in the medical practice of many countries around the world including Japan, Russia, France, and Switzerland. Indications for use include stroke, traumatic brain injuries, and organic brain syndrome. Citicoline works by increasing the synthesis of phosphatidylcholine (the primary component of neuronal cell membranes) and acetylcholine - a major neurotransmitter involved in cognitive functioning.
Various forms of choline are also often used as cognitive enhancing supplements. However, cheaper forms such as Lecithin and Choline salts have limited nootropic value, as they have a less pronounced cholinergic effect and no impact on monoaminergic neurotransmission.
- M Fioravanti, A Buckley (2006) Citicoline (Cognizin) in the treatment of cognitive impairment https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695184/
- Gavrilova et al (2011) Ceraxon (citicoline) in the treatment of the mild cognitive impairment syndrome https://www.ncbi.nlm.nih.gov/pubmed/22433803
- Martynov et al (2013) Neuroprotective Therapy with Citicoline (Ceraxon) in Patients with Ischemic Stroke https://link.springer.com/article/10.1007/s11055-013-9797-x
- J Nasiri, M Kargar (2014) Combination of Citicoline and Physiotherapy in Children with Cerebral Palsy https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223951/
- Rubtsova et al (2014) Study of efficiency of ceraxon in the treatment of lag psychomotor development of children with hypoxic-ischemic lesions of central nervous system https://www.ncbi.nlm.nih.gov/pubmed/25796838
- Secades et al (2016) Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials https://www.researchgate.net/publication/303509170_Citicoline_for_Acute_Ischemic_Stroke_A_Systematic_Review_and_Formal_Meta-analysis_of_Randomized_Double-Blind_and_Placebo-Controlled_Trials
- Mashin et al (2017) Multicenter observational program for evaluation of the effectiveness of the recognan (citicoline) in the correction of cognitive impairment in patients with chronic cerebrovascular pathology https://www.ncbi.nlm.nih.gov/pubmed/28884715
- Nemkova et al (2018) Cognitive and emotional disorders in university students and teachers: the possibility of treatment with recognan (citicoline) https://www.ncbi.nlm.nih.gov/pubmed/30698554